Christopher B. Dechet

Christopher B. Dechet

Auto-generated profile, based on publicly available information

Christopher B. Dechet

Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
CAChristopher J. Anker
Christopher J. Anker
CDChristopher Dechet
Christopher Dechet
JIJorge C. Isaac
Jorge C. Isaac
WAWallace Akerley
Wallace Akerley
DSDennis C. Shrieve
Dennis C. Shrieve

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
SGSamantha Greenberg
Samantha Greenberg
THTrevor C. Hunt
Trevor C. Hunt
JAJacob P. Ambrose
Jacob P. Ambrose
WLWilliam T. Lowrance
William T. Lowrance
CDChristopher B. Dechet
Christopher B. Dechet
JTJonathan David Tward
Jonathan David Tward
PURPOSE: Germline likely pathogenic or pathogenic variants (PVs) have been identified in up to 17% of men with prostate cancer (PC) and may drive disease severity or be targetable by novel therapies. National Comprehensive Cancer Network (NCCN) guidelines encouraging germline testing in metastatic PC were recently expanded to include all men with high-risk, very high-risk, or regional PC. Our aim was to assess the impact of expanded NCCN guidelines on the detection rate of germline PVs and to determine patient-level factors associated with a PV germline testing result. PATIENTS AND METHODS: Men with PC underwent multigene germline genetic testing for PVs from June 2016 to December 2018, and trends were compared. The association of patient-level factors with a PV germline testing result, where ≥ 1 PV was identified, was assessed using analysis of variance and univariate logistic regression. Sensitivity analyses were limited to clinically actionable variants and those associated with disease severity or progression ( BRCA1/2 and ATM). RESULTS: Of 408 men undergoing germline testing, 42 (10.3%) men had PVs and 366 (89.7%) men did not have PVs identified. The proportion of men identified with a germline PV remained stable following testing criteria expansion (9.4% v 10.6%, P = .73). No patient-level factors were significantly associated with increased odds of a PV germline testing result, including age at diagnosis, race, pretreatment prostate-specific antigen, Gleason grade group, NCCN risk group, and family history of cancer (breast and/or ovarian, prostate, or any cancer). CONCLUSION: This study demonstrated a stable PV detection rate in men with PC using expanded criteria aligned to the updated NCCN testing guidelines. However, we did not find strong evidence to suggest that patient-level factors are associated with PV germline testing results. These findings support the recent expansion of NCCN germline testing guidelines in PC.

20 February 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SGSumati Gupta
Sumati Gupta
BMBenjamin L. Maughan
Benjamin L. Maughan
CDChristopher B. Dechet
Christopher B. Dechet
WLWilliam Thomas Lowrance
William Thomas Lowrance
BNBrock O Neil
Brock O Neil
NANeeraj Agarwal
Neeraj Agarwal
TPS605 Background: In pts with localized muscle invasive bladder cancer (MIBC), trimodality bladder preserving therapy (TMT), with transurethral resection of bladder tumor, radio-sensitizing chemotherapy and definitive radiation, has up to a 50% risk of local and systemic relapse during the 2-year post treatment phase. We hypothesize that by inhibiting immune checkpoints, chemo-radiation induced tumor specific immune response will be enhanced both locally and abscopally, resulting in better failure-free survival (FFS). In the NEXT trial, we evaluate the efficacy of nivolumab after completion of the TMT in this setting. Methods: Pts with localized MIBC who have completed standard TMT are eligible. Pts receive nivolumab 480 mg intravenously every 4 weeks for up to 12 doses. Treatment with nivolumab begins within 90 days of completion of TMT. Subjects undergo surveillance cystoscopic and scan based assessments on study. Archived tumor tissue at baseline and at relapse is obtained for correlative studies. The primary endpoint is 2-year FFS. Secondary endpoints include FFS at 2 years in patients with intact bladder, rate of radical cystectomy (RC), cystoscopic local control, distant FFS in patients with intact bladder and those that undergo RC, overall survival, toxicity and quality of life. Exploratory endpoints include to characterize changes in immune cell subsets that can be correlated with clinical outcome and to assess the correlation of response to PD-L1 expression in pretreatment tumor tissue in the study subjects. The planned sample size for this single arm, open label trial is 28 pts. Kaplan-Meier methods will be used to plot survival endpoints and cystoscopic local control rates. Exact binomial methods will be used to provide 6 months, 1-year and 2-year estimates for these endpoints. The sample size justification is based on the maximum width of a two-sided 95% binomial confidence interval for 2 year FFS. With 28 evaluable subjects, a 95% exact binomial confidence interval, estimated using the method of Clopper-Pearson, will extend no more than 20% from the observed FFS. Clinical trial information: NCT03171025.

1 March 2013 in European Urology Supplements
Verified
Journal Article
Closed access
ECE. Comploj
E. Comploj
CMC. Mian
C. Mian
ASAmbrosini A. Spaltro
Ambrosini A. Spaltro
CDC. Dechet
C. Dechet
SPS. Palermo
S. Palermo
APA. Pycha
A. Pycha